MC1568

While class I HDACs are localized predominantly within the nucleus, class II HDACs shuttle into and out of the nucleus in response to intracellular signaling. Class IIa HDACs, which includes HDAC4, 5, 7, and 9, commonly act as corepressors and play diverse roles in cell biology. MC 1568 is a selective inhibitor of class IIa HDACs, with greater than 170-fold selectivity over class I HDACs, including HDAC1. It has been used in cells (1-10 μM) and in mice to elucidate the roles of class IIa HDACs in cell proliferation and differentiation, apoptosis, myogenesis, adipogenesis, and fibrosis.

While class I HDACs are localized predominantly within the nucleus, class II HDACs shuttle into and out of the nucleus in response to intracellular signaling. Class IIa HDACs, which includes HDAC4, 5, 7, and 9, commonly act as corepressors and play diverse roles in cell biology. MC 1568 is a selective inhibitor of class IIa HDACs, with greater than 170-fold selectivity over class I HDACs, including HDAC1. It has been used in cells (1-10 μM) and in mice to elucidate the roles of class IIa HDACs in cell proliferation and differentiation, apoptosis, myogenesis, adipogenesis, and fibrosis.[Cayman Chemical]

A selective class II (IIa) histone deacetylase (HDAC II) inhibitor. It exhibits tissue-selective inhibition between members of class II acetylases in vivo, particularly in skeletal muscle and the heart. It arrests myogenesis through the stabilization of myocyte enhancer factor 2D (MEF2D)-HDAC3/4 complex.

ChEBI: 3-[4-[3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methyl-2-pyrrolyl]-N-hydroxy-2-propenamide is a carbonyl compound.

MC1568 is a selective class II (IIa) histone deacetylas (HDAC II) inhibitor.

+4°C

[1] ANTONELLO MAI. Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides[J]. Journal of Medicinal Chemistry, 2005, 48 9: 3344-3353. DOI: 10.1021/jm049002a
[2] ANTONELLO MAI. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia.[J]. Molecular Pharmacology, 2007, 72 5: 1111-1123. DOI: 10.1124/mol.107.036772
[3] ANGELA NEBBIOSO. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes.[J]. EMBO Reports, 2009, 10 7: 776-782. DOI: 10.1038/embor.2009.88
[4] VANESSA DUONG. Specific activity of class II histone deacetylases in human breast cancer cells.[J]. Molecular Cancer Research, 2008, 6 12: 1908-1919. DOI: 10.1158/1541-7786.mcr-08-0299
[5] ANGELA NEBBIOSO. HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation.[J]. Journal of molecular endocrinology, 2010, 45 4: 219-228. DOI: 10.1677/jme-10-0043
[6] GUAN WANG. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.[J]. PLoS ONE, 2012: e52095. DOI: 10.1371/journal.pone.0052095
[7] INGE MANNAERTS. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29.[J]. PLoS ONE, 2013: e55786. DOI: 10.1371/journal.pone.0055786
[8] FRANCESCO SPALLOTTA. Detrimental effect of class-selective histone deacetylase inhibitors during tissue regeneration following hindlimb ischemia.[J]. The Journal of Biological Chemistry, 2013, 288 32: 22915-22929. DOI: 10.1074/jbc.m113.484337